Factors associated with fibroblast growth factor 19 increment after oral glucose loading in patients who were previously admitted for coronary angiography.
BACKGROUND
We investigated factors associated with fibroblast growth factor 19 (FGF-19) increment after oral glucose loading (OGL) in human subjects.


METHODS
A total of 240 outpatients without known diabetes who were previously admitted for coronary angiography underwent an oral glucose tolerance test. FGF-19 increment (pg/ml) was calculated as FGF-19 2h after OGL minus fasting FGF-19.


RESULTS
Overall, FGF-19 significantly increased after OGL (from 123 [78-201] to 141 [80-237], p=0.001). By age tertiles (≦ 54, 55-64, ≧ 65), FGF-19 significantly increased only in patients aged ≧ 65 (from 143 [98-209] to 189 [124-332], p<0.001). By glucose regulation status, FGF-19 significantly increased in patients with normal glucose tolerance (from 117 [78-211] to 153 [106-325], p=0.014) and in patients with prediabetes (from 117 [73-179] to 123 [70-204], p=0.043), but not in patients with diabetes (from 181 [102-243] to 178 [111-275], p=0.139). FGF-19 significantly increased in patients on statin treatment (from 120 [78-207] to 145 [86-264], p<0.001), but not in patients not on statin therapy (from 125 [86-196] to 128 [68-230] pg/ml, p=0.676). These findings remained significant after adjustment for confounders.


CONCLUSIONS
FGF-19 increment after OGL was positively associated with age, and negatively associated with abnormal glucose regulation and statin treatment.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Jun-Sing
JS
Wang
Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Public Health, College of Public Health, China Medical University, Taichung, Taiwan.
Chia-Lin
CL
Lee
Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
Wen-Jane
WJ
Lee
Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Medicine, School of Medicine, Natonal Yang-Ming University, Taipei, Taiwan; Department of Medicine, School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
I-Te
IT
Lee
Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Medicine, School of Medicine, Natonal Yang-Ming University, Taipei, Taiwan.
Shih-Yi
SY
Lin
Cardiovascular Center, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Medicine, School of Medicine, Natonal Yang-Ming University, Taipei, Taiwan.
Wen-Lieng
WL
Lee
Cardiovascular Center, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Medicine, School of Medicine, Natonal Yang-Ming University, Taipei, Taiwan; Department of Medicine, School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Kae-Woei
KW
Liang
Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Medicine, School of Medicine, Natonal Yang-Ming University, Taipei, Taiwan; Department of Medicine, School of Medicine, Chung Shan Medical University, Taichung, Taiwan; Institute of Medical Technology, College of Life Science, National Chung-Hsing University, Taichung, Taiwan; School of Medicine, National Defense Medical Center, Taipei, Taiwan. Electronic address: whhsheu@vghtc.gov.tw.
Wayne Huey-Herng
WH
Sheu
D017023:Coronary Angiography; D003920:Diabetes Mellitus / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy; D005260:Female; D005346:Fibroblast Growth Factors / Q000097:blood*; D005951:Glucose Tolerance Test; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
C117476:FGF19 protein, human; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D005346:Fibroblast Growth Factors
Abnormal glucose regulation; Age; Coronary angiography; Diabetes; Fibroblast growth factor 19; Oral glucose loading